12.16: Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced activity of penicillins when administered with probenecid. These interactions are crucial to monitor to ensure safe and effective use of medications.

Drug–drug interactions (DDIs) are a significant aspect of pharmacology that occur when the presence of one drug alters another’s effects. These interactions can significantly influence the pharmacokinetic properties of drugs, affecting their absorption, distribution, metabolism, and excretion, ultimately impacting therapeutic efficacy and safety. For example, interactions between antiretroviral drugs and other medications can complicate therapy. Ritonavir, used to inhibit HIV protease, also inhibits CYP3A4, thereby increasing the plasma levels of other drugs metabolized by this enzyme, such as certain sedatives, necessitating careful monitoring and dosage adjustments. Additionally, using antiemetic agents like aprepitant in chemotherapy can also inhibit CYP3A4, affecting the metabolism of chemotherapeutic agents, which may require dose modifications to maintain efficacy and reduce toxicity. Drug-drug interactions can involve:

1. Pharmacokinetic Interactions: These interactions influence the ADME (Absorption, Distribution, Metabolism, Excretion) processes of a drug. For example, antacids can reduce the absorption of tetracyclines by forming unabsorbable complexes, leading to decreased efficacy of the antibiotic.
2. Pharmacodynamic Interactions: These occur when two drugs given together act at the same or interrelated receptor sites, resulting in additive, synergistic, or antagonistic effects. For instance, the simultaneous administration of two antihypertensive drugs can produce a greater hypotensive effect than either drug alone.

Drug-drug interactions can occur via various mechanisms, such as:

1. Enzyme Inhibition: Some drugs can inhibit the action of enzymes necessary for the metabolism of other drugs, thereby increasing their blood levels and potential toxicity. A notable example is the inhibition of CYP3A4 by ketoconazole, which increases the levels of drugs metabolized by this enzyme, such as certain statins, leading to an increased risk of side effects like rhabdomyolysis.
2. Enzyme Induction: Certain drugs can increase metabolizing enzyme levels, reducing the efficacy of other drugs. For example, rifampin induces the production of CYP450 enzymes, leading to reduced blood levels of drugs like oral contraceptives, thereby decreasing their effectiveness.
3. Altered Drug Transport: Drugs can also interact by altering the activity of drug transporters. For example, verapamil, a calcium channel blocker, inhibits P-glycoprotein, a transporter protein, enhancing the effects of drugs like digoxin, which could lead to toxicity.

Understanding and managing such interactions is crucial for maximizing therapeutic efficacy and minimizing adverse effects in clinical settings. Healthcare professionals must be vigilant about potential interactions and adjust drug regimens to ensure safe and effective patient care.

Drug interactions occur when another substance alters a drug's effects.

A drug–drug interaction happens when one drug alters another’s activity, reducing efficacy or increasing adverse effects.

Occasionally, interactions can be beneficial, like enhanced penicillin activity on coadministration with probenecid.

Pharmacokinetic interactions affect drug absorption, distribution, metabolism, and excretion. For example, antacids reduce tetracycline efficacy by forming unabsorbable complexes in the gut.

Pharmacodynamic interactions involve drugs acting at the same or related receptor sites, leading to additive, synergistic, or antagonistic effects.

Enzyme inhibition and induction alter drug metabolism, impacting plasma drug levels and activity. For example, ketoconazole inhibits CYP3A4, increasing toxicity risk for drugs metabolized by this enzyme.

Additionally, some drugs modify transporter activity, impacting drug absorption and elimination. For example, verapamil inhibits P-glycoprotein, potentially causing digoxin toxicity.